Literature DB >> 21513436

Co-morbidity, body mass index and quality of life in COPD using the Clinical COPD Questionnaire.

Josefin Sundh1, Björn Ställberg, Karin Lisspers, Scott M Montgomery, Christer Janson.   

Abstract

INTRODUCTION: Quality of life is an important patient-oriented measure in COPD. The Clinical COPD Questionnaire (CCQ) is a validated instrument for estimating quality of life. The impact of different factors on the CCQ-score remains an understudied area. The aim of this study was to investigate the association of co-morbidity and body mass index with quality of life measured by CCQ.
METHODS: A patient questionnaire including the CCQ and a review of records were used. A total of 1548 COPD patients in central Sweden were randomly selected. Complete data were collected for 919 patients, 639 from primary health care and 280 from hospital clinics. Multiple linear regression with adjustment for sex, age, level of education, smoking habits and level of care was performed. Subanalyses included additional adjustment for lung function in the subgroup (n = 475) where spirometry data were available.
RESULTS: Higher mean CCQ score indicating lower quality of life was statistically significant and independently associated with heart disease (adjusted regression coefficient (95%CI) 0.26; 0.06 to 0.47), depression (0.50; 0.23 to 0.76) and underweight (0.58; 0.29 to 0.87). Depression and underweight were associated with higher scores in all CCQ subdomains. Further adjustment for lung function in the subgroup with this measure resulted in statistically significant and independent associations with CCQ for heart disease, depression, obesity and underweight.
CONCLUSION: The CCQ identified that heart disease, depression and underweight are independently associated with lower health-related quality of life in COPD.

Entities:  

Mesh:

Year:  2011        PMID: 21513436     DOI: 10.3109/15412555.2011.560130

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  31 in total

Review 1.  An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease.

Authors:  François Maltais; Marc Decramer; Richard Casaburi; Esther Barreiro; Yan Burelle; Richard Debigaré; P N Richard Dekhuijzen; Frits Franssen; Ghislaine Gayan-Ramirez; Joaquim Gea; Harry R Gosker; Rik Gosselink; Maurice Hayot; Sabah N A Hussain; Wim Janssens; Micheal I Polkey; Josep Roca; Didier Saey; Annemie M W J Schols; Martijn A Spruit; Michael Steiner; Tanja Taivassalo; Thierry Troosters; Ioannis Vogiatzis; Peter D Wagner
Journal:  Am J Respir Crit Care Med       Date:  2014-05-01       Impact factor: 21.405

Review 2.  Sleep disorders in chronic obstructive pulmonary disease: etiology, impact, and management.

Authors:  Rohit Budhiraja; Tauseef A Siddiqi; Stuart F Quan
Journal:  J Clin Sleep Med       Date:  2015-03-15       Impact factor: 4.062

3.  Comorbidities of COPD have a major impact on clinical outcomes, particularly in African Americans.

Authors:  Nirupama Putcha; Meilan K Han; Carlos H Martinez; Marilyn G Foreman; Antonio R Anzueto; Richard Casaburi; Michael H Cho; Nicola A Hanania; Craig P Hersh; Gregory L Kinney; Barry J Make; Robert M Steiner; Sharon M Lutz; Byron M Thomashow; Andre A Williams; Surya P Bhatt; Terri H Beaty; Russell P Bowler; Joe W Ramsdell; Jeffrey L Curtis; Douglas Everett; John E Hokanson; David A Lynch; E Rand Sutherland; Edwin K Silverman; James D Crapo; Robert A Wise; Elizabeth A Regan; Nadia N Hansel
Journal:  Chronic Obstr Pulm Dis       Date:  2014

4.  The Dyspnoea, Obstruction, Smoking, Exacerbation (DOSE) index is predictive of mortality in COPD.

Authors:  Josefin Sundh; Christer Janson; Karin Lisspers; Björn Ställberg; Scott Montgomery
Journal:  Prim Care Respir J       Date:  2012-09

5.  Correlation between disease severity factors and EQ-5D utilities in chronic obstructive pulmonary disease.

Authors:  Cristina Esquinas; Maria A Ramon; Alexa Nuñez; Jesús Molina; José A Quintano; Miguel Roman-Rodríguez; Karlos Naberan; Carl Llor; Carlos Roncero; Marc Miravitlles; Miriam Barrecheguren
Journal:  Qual Life Res       Date:  2019-10-31       Impact factor: 4.147

6.  Clinical COPD Questionnaire score (CCQ) and mortality.

Authors:  Josefin Sundh; Christer Janson; Karin Lisspers; Scott Montgomery; Björn Ställberg
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-12-20

7.  Clinical and economic outcomes for patients initiating fluticasone propionate/salmeterol combination therapy (250/50 mcg) versus anticholinergics in a comorbid COPD/depression population.

Authors:  Anand A Dalal; Manan Shah; Anna O D'Souza; Sham Chaudhari; Glenn Crater
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-01-18

Review 8.  Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease.

Authors:  Marc Miravitlles; David Price; Klaus F Rabe; Hendrik Schmidt; Norbert Metzdorf; Bartolome Celli
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-03-16

Review 9.  Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony.

Authors:  Aibek E Mirrakhimov
Journal:  Cardiovasc Diabetol       Date:  2012-10-27       Impact factor: 9.951

10.  The phenotype of concurrent chronic bronchitis and frequent exacerbations in patients with severe COPD attending Swedish secondary care units.

Authors:  Josefin Sundh; Gunnar Johansson; Kjell Larsson; Anders Lindén; Claes-Göran Löfdahl; Thomas Sandström; Christer Janson
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.